Informations générales (source: ClinicalTrials.gov)
Phase III Randomized Clinical Trial for Stage III Epithelial Ovarian Cancer Randomizing Between Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (OVHIPEC-2)
Interventional
Phase 3
The Netherlands Cancer Institute (Voir sur ClinicalTrials)
janvier 2020
avril 2026
29 juin 2024
stage III epithelial ovarian cancer randomizing between primary cytoreductive surgery
with or without hyperthermic intraperitoneal chemotherapy
Etablissements
| Les établissements d'Île-de-France ayant mis à jour leurs données Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| CLCC INSTITUT CURIE | 10/04/2025 13:12:11 | Contacter | |||
| Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| Centre Leon Berard, Lyon - Lyon - France | Nabila B Bouazza | Contact (sur clinicalTrials) | |||
| CHRU Strasbourg - Strasbourg - France | Nabila Bouazza | Contact (sur clinicalTrials) | |||
| CHU de Besancon - Besançon - France | Nabila Bouazza | Contact (sur clinicalTrials) | |||
| CHU Lille - Lille - France | Nabila Bouazza | Contact (sur clinicalTrials) | |||
| CHU Lyon - Lyon - France | Nabila B Bouazza | Contact (sur clinicalTrials) | |||
| Institut Bergonié - Bordeaux - France | Nabila Bouazza | Contact (sur clinicalTrials) | |||
| Institut de Cancerologie de l'Ouest, ICO Nantes) - Nantes - France | Nabila Bouazza | Contact (sur clinicalTrials) | |||
| Institut du Cancer Montpellier - Montpellier - France | Nabila Bouazza | Contact (sur clinicalTrials) | |||
| o Institut Bergonié, Bordeaux - Bordeaux - France | Nabila Bouazza | Contact (sur clinicalTrials) | |||
| Oncopole, Institute Universitaire du Cancer de Toulouse (IUCT Toulouse) - Toulouse - France | Nabila Bouazza | Contact (sur clinicalTrials) | |||
Critères
Femme
Inclusion Criteria:
- candidate for primary CRS
- histological or cytological proven FIGO stage III primary epithelial ovarian,
fallopian tube, or extra-ovarian cancer
- candidate for primary CRS
- histological or cytological proven FIGO stage III primary epithelial ovarian,
fallopian tube, or extra-ovarian cancer
- history of previous malignancies within 5 years prior to inclusion
- FIGO stage IV disease
- complete primary cytoreduction is impossible
- prior treatment for the current malignancy